These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 7711129)

  • 1. [Drugs: piperacillin/tazobactam].
    Enferm Infecc Microbiol Clin; 1995 Feb; 13(2):132-3. PubMed ID: 7711129
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection.
    DeRyke CA; Kuti JL; Mansfield D; Dana A; Nicolau DP
    Am J Health Syst Pharm; 2006 Apr; 63(8):750-5. PubMed ID: 16595817
    [No Abstract]   [Full Text] [Related]  

  • 3. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():1-124. PubMed ID: 8383650
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
    Liu Q; Rand K; Derendorf H
    Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
    Attivi D; Gibaud S
    Ann Pharm Fr; 2014 May; 72(3):146-51. PubMed ID: 24780830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally administered recombinant metallo-beta-lactamase preserves colonization resistance of piperacillin-tazobactam-treated mice.
    Stiefel U; Harmoinen J; Koski P; Kääriäinen S; Wickstrand N; Lindevall K; Pultz NJ; Bonomo RA; Helfand MS; Donskey CJ
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5190-1. PubMed ID: 16304203
    [No Abstract]   [Full Text] [Related]  

  • 8. The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.
    Kotapati S; Kuti JL; Geissler EC; Nightingale CH; Nicolau DP
    Intensive Crit Care Nurs; 2005 Apr; 21(2):87-93. PubMed ID: 15778072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piperacillin/tazobactam compared with cefuroxime/ metronidazole in the treatment of intra-abdominal infections.
    Ohlin B; Cederberg A; Forssell H; Solhaug JH; Tveit E
    Eur J Surg; 1999 Sep; 165(9):875-84. PubMed ID: 10533765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
    Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
    Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of piperacillin and tazobactam combination against clinically significant bacteria.
    Obi CL; Makandiramba B; Robertson V; Tswana SA; Moyo SR; Nziramasanga P
    East Afr Med J; 1998 Mar; 75(3):162-5. PubMed ID: 9640815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group.
    Polk HC; Fink MP; Laverdiere M; Wilson SE; Garber GE; Barie PS; Hebert JC; Cheadle WG
    Am Surg; 1993 Sep; 59(9):598-605. PubMed ID: 8396374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations.
    Dalla Costa T; Nolting A; Rand K; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):426-33. PubMed ID: 9352391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam.
    Pournaras S; Ikonomidis A; Neou E; Kantzanou M; Maniatis AN; Tsakris A
    J Antimicrob Chemother; 2008 Mar; 61(3):757-8. PubMed ID: 18199562
    [No Abstract]   [Full Text] [Related]  

  • 15. [Piperacillin-tazobactam in the treatment of severe nosocomial infections].
    Venditti M; Cassone M; Falcone M; Pavoni G; Pistella E; Paris A
    Recenti Prog Med; 2002 Mar; 93(3):200-11. PubMed ID: 11942173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakpoint determination: piperacillin/tazobactam.
    Eur J Clin Microbiol Infect Dis; 1993 Jul; 12(7):575-7. PubMed ID: 8404929
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacological properties and clinical efficacies of tazobactam/piperacillin (Zosyn 2.25, Zosyn 4.5), an injectable antibiotic combined with beta-lactamase inhibitor].
    Uji T; Hashimoto Y
    Nihon Yakurigaku Zasshi; 2009 Jun; 133(6):351-8. PubMed ID: 19521033
    [No Abstract]   [Full Text] [Related]  

  • 18. Detection of bacterial strains producing sulbactam- or tazobactam-sensitive beta-lactamases by the use of disks containing the inhibitors alone instead of combining them with antibiotics.
    Banic S
    APMIS; 2006 Jan; 114(1):3-9. PubMed ID: 16499654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
    Grant EM; Kuti JL; Nicolau DP; Nightingale C; Quintiliani R
    Pharmacotherapy; 2002 Apr; 22(4):471-83. PubMed ID: 11939682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Beta-lactamase inhibitor: tazobactam].
    Zhang YL; Li JT
    Sheng Li Ke Xue Jin Zhan; 1997 Oct; 28(4):370-3. PubMed ID: 11038697
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.